| Literature DB >> 29392141 |
Niwat Saksit1,2, Nontaya Nakkam1, Parinya Konyoung3, Usanee Khunarkornsiri3, Wongwiwat Tassaneeyakul4, Pansu Chumworathayi5, Sirimas Kanjanawart1, Chonlaphat Sukasem6,7, Alisara Sangviroon8, Oranuch Pattanacheewapull9, Wichittra Tassaneeyakul1.
Abstract
Severe cutaneous adverse drug reactions (SCARs) are life-threatening reactions. The strong association between the HLA-B∗58 : 01 allele and allopurinol-induced SCARs is well recognized. Screening for HLA-B∗58 : 01 allele before prescribing allopurinol in some populations has been recommended. Several single-nucleotide polymorphisms (SNPs) in chromosome 6 have been found to be tightly linked with the HLA allele, and these SNPs have been proposed as surrogate markers of the HLA-B∗58 : 01 allele. This study aimed to evaluate the association between three SNPs in chromosome 6 and allopurinol-induced SCARs in a Thai population. The linkage disequilibrium between the HLA-B∗58 : 01 allele and these SNPs was also evaluated. Results showed that three SNPs including rs9263726, rs2734583, and rs3099844 were significantly associated with allopurinol-induced SCARs but with a lower degree of association when compared with the HLA-B∗58 : 01 allele. The sensitivity, specificity, PPV, and NPV of these SNPs were comparable to those of the HLA-B∗58 : 01 allele. Although detection of the SNP is simpler and less expensive compared with that of the HLA-B∗58 : 01 allele, these SNPs were not perfectly linked with the HLA-B∗58 : 01 allele. Screening using these SNPs as surrogate markers of the HLA-B∗58 : 01 allele to avoid SCARs prior to allopurinol administration needs caution because of their imperfect linkage with the HLA-B∗58 : 01 allele.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29392141 PMCID: PMC5748122 DOI: 10.1155/2017/2738784
Source DB: PubMed Journal: J Immunol Res ISSN: 2314-7156 Impact factor: 4.818
Demographic and clinical characteristics of allopurinol-induced SCARs and tolerant control patients.
| Characteristic data | DRESS ( | SJS/TEN ( | SCARs ( | Control ( | |
|---|---|---|---|---|---|
| Age (year) | Mean (SD) | 65 (14) | 65 (12) | 65 (12) | 64 (12) |
| Median (range) | 68 (28–82) | 68 (38–84) | 68 (28–84) | 66 (29–91) | |
| Gender | Female; | 10 (43.48) | 40 (54.79)∗∗∗∗∗ | 50 (52.08)∗∗∗∗∗ | 49 (25.39) |
| Onset of SCARs (day) | Mean (SD) | 29 (13) | 19 (11) | 21 (13) | — |
| Median (range) | 30 (10–60)∗∗∗∗∗ | 18 (2–60)∗∗∗∗∗ | 20 (2–60)∗∗∗∗∗ | — | |
| Allopurinol dose (mg) | Mean (SD) | 171 (78) | 182 (106) | 179 (99) | 194 (90) |
| Median (range) | 200 (100–300) | 100 (50–600) | 100 (50–600) | 200 (100–600) | |
| Indication of allopurinol | Hyperuricemia; | 11 (47.83)∗∗∗∗∗ | 13 (17.81)∗∗∗∗∗ | 24 (25.00)∗∗∗∗∗ | 3 (1.55) |
| Gouty arthritis; | 12 (52.17) | 60 (82.19) | 72 (75.00) | 190 (98.45) | |
|
| |||||
| Blood urine nitrogen (mg/dL) |
|
|
|
|
|
| Mean (SD) | 29.79 (21.14) | 24.85 (20.09) | 26.58 (20.33) | 18.63 (10.40) | |
| Median (range) | 21.35 (11.00–80.00) | 18.50 (10.00–105.00) | 21.00 (10.00–105.00)∗ | 16.20 (3.00–70.00) | |
| Serum creatinine (mg/dL) |
|
|
|
|
|
| Mean (SD) | 2.20 (2.20) | 1.54 (1.05) | 1.69 (1.40) | 1.47 (1.46) | |
| Median (range) | 1.40 (0.90–9.60) | 1.30 (0.50–8.82) | 1.30 (0.50–9.60) | 1.20 (0.70–14.80) | |
| Estimated glomerular filtration rate (eGFR) (mL/min/1.73 m2)a |
|
|
|
|
|
| Mean (SD) | 44.05 (21.99) | 48.61 (21.95) | 47.58 (21.91) | 58.01 (20.41) | |
| Median (range) | 46.00 (6.54–88.61)∗∗ | 45.27 (4.62–127.17)∗∗ | 45.65 (4.62–127.17)∗∗∗ | 57.45 (3.12–112.49) | |
| eGFR < 30.00; | 4 (17.39) | 14 (19.18)∗∗ | 18 (21.43)∗∗ | 13 (7.47) | |
| 30.00 ≤ eGFR < 60.00; | 11 (47.83) | 37 (50.68)∗ | 48 (57.14) | 78 (44.83) | |
| eGFR ≥ 60.00; | 4 (17.39)∗ | 14 (19.18)∗∗∗ | 18 (21.43)∗∗∗∗ | 83 (47.70) |
aeGFR: estimated glomerular filtration rate (expressed as mL/min/1.73 m2) calculated by Modification of Diet in Renal the Disease (MDRD) study equation [39]. Indicated significant difference between case and tolerant control. ∗P value < 0.05, ∗∗P value < 0.01, ∗∗∗P value < 0.001, ∗∗∗∗P value < 0.0001, and ∗∗∗∗∗P value < 0.00001.
Univariate analysis of the association between HLA-B∗58 : 01 allele and SNPs with allopurinol-induced SCARs.
| Allele/SNPs | Control ( | DRESS ( | SJS/TEN ( | SCARs ( | ||||
|---|---|---|---|---|---|---|---|---|
|
|
| OR |
| OR |
| OR | ||
|
| Negative | 170 (88.08) | 2 (8.70) | Reference | 4 (5.48) | Reference | 6 (6.25) | Reference |
| Positive | 23 (11.92) | 21 (91.30) | 77.61 | 69 (94.52) | 127.50 | 90 (93.75) | 110.87 | |
|
| ||||||||
| rs9263726 (G/A) | Negative (GG) | 159 (82.38) | 4 (17.39) | Reference | 5 (6.85) | Reference | 9 (9.38) | Reference |
| Positive (GA/AA) | 34 (17.62) | 19 (82.61) | 22.21 | 68 (93.15) | 63.60 | 87 (90.63) | 45.21 | |
|
| ||||||||
| rs2734583 (T/C) | Negative (TT) | 166 (86.01) | 2 (8.70) | Reference | 7 (9.59) | Reference | 9 (9.37) | Reference |
| Positive (TC/CC) | 27 (13.99) | 21 (91.30) | 64.56 | 66 (90.41) | 57.97 | 87 (90.63) | 59.43 | |
|
| ||||||||
| rs3099844 (C/A) | Negative (CC) | 164 (84.97) | 2 (8.70) | Reference | 7 (9.59) | Reference | 9 (9.38) | Reference |
| Positive (CA/AA) | 29 (15.03) | 21 (91.30) | 59.38 | 66 (90.41) | 53.32 | 87 (90.63) | 54.67 | |
|
| ||||||||
| SNPs haplotypes (rs9263726-rs2734583-rs3099844) | GG-TT-CC | 156 (80.83) | 2 (8.70) | Reference | 4 (5.48) | Reference | 6 (6.25) | Reference |
| GA-TC-CA | 24 (12.44) | 16 (69.57) | 52.00 | 61 (83.56) | 99.13 | 77 (80.21) | 83.42 | |
Pc-value: Bonferroni-corrected P value, calculated by multiplying P value by 4 which is the number of detected SNPs.
Properties of proposed genetic screening tests for prediction of allopurinol-induced SCARs in a Thai population.
| Allele/SNPs | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DRESS | SJS/TEN | SCARs | DRESS | SJS/TEN | SCARs | DRESS | SJS/TEN | SCARs | DRESS | SJS/TEN | SCARs | |
|
| 91.30 | 94.52 | 93.75 | 88.08 | 88.08 | 88.08 | 47.73 | 75.00 | 79.65 | 98.84 | 97.70 | 96.59 |
| rs9263726 (G/A) | 82.61 | 93.15 | 90.63 | 82.38 | 82.38 | 82.38 | 35.85 | 66.67 | 71.90 | 97.55 | 96.95 | 94.64 |
| rs2734583 (T/C) | 91.30 | 90.41 | 90.63 | 86.01 | 86.01 | 86.01 | 43.75 | 70.97 | 76.32 | 98.81 | 95.95 | 94.86 |
| rs3099844 (C/A) | 91.30 | 90.41 | 90.63 | 84.97 | 84.97 | 84.97 | 42.00 | 69.47 | 75.00 | 98.80 | 95.91 | 94.80 |
| SNPs haplotypes (rs9263726-rs2734583-rs3099844) | ||||||||||||
| GA-TC-CA | 69.57 | 83.56 | 80.21 | 87.56 | 87.56 | 87.56 | 40.00 | 71.76 | 76.24 | 96.02 | 93.37 | 89.89 |
Data presented as percentage. PPV: positive predictive value; NPV: negative predictive value.
Concordance between selected SNPs and HLA-B allele in allopurinol-induced SCARs.
| SNP | Disequilibrium coefficient ( | Coefficient of correlation ( | ||||||
|---|---|---|---|---|---|---|---|---|
| DRESS ( | SJS/TEN ( | SCARs ( | Control ( | DRESS ( | SJS/TEN ( | SCARs ( | Control ( | |
| rs9263726 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 0.4524 | 0.7884 | 0.6444 | 0.6327 |
| rs2734583 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 0.5466 | 0.6444 | 0.8318 |
| rs3099844 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 0.5466 | 0.6444 | 0.7651 |